Ireland· IE-PA-PA22865/006/001
Carbimazole 5 mg Tablets
A carbimazole product containing carbimazole, registered in Ireland by Renata Pharmaceuticals (Ireland) Limited. The same ATC class is registered in 8 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Carbimazole is registered in 8 of 19 countries.
Countries holding a registration under ATC H03BB01 (carbimazole), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 4 of them publish a price we can compare per daily dose
Carbimazole · ATC H03BB01
8 / 19 countries
- Denmark
- Finlandprice
- Franceprice
- Germany
- Ireland
- Norwayprice
- Switzerlandprice
- United Kingdom
Price per daily dose
What a daily dose of carbimazole costs, country by country.
Normalised to the WHO defined daily dose (15 mg), the median price runs from $0.15 in France to $0.94 in Switzerland — a ×6.3 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Carbimazole · price per daily dose (15 mg)
USD · FX 28 Sept 2026
- CH Switzerland$0.94
- FR France$0.15
The record
At a glance
HPRA (Ireland)- Active substance
- Carbimazole
- Manufacturer
- Renata Pharmaceuticals (Ireland) Limited
- Country
- Ireland (IE)
- ATC code
- H03BB01
- ATC class
- Carbimazole
- Defined daily dose
- 15 mg, O
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberPA22865/006/001
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Carbimazole in 7 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomCarbimazole 5mg tabletsA A H Pharmaceuticals Ltd
- FinlandTyrazolOrion Corporation
- SwitzerlandNéo-Mercazole, TablettenAdvanz Pharma Specialty Medicine Switzerland GmbH
- NorwayCarbimazolsanofi-aventis (2)
- FranceNEO-MERCAZOLE 5 mg, compriméAMDIPHARM
- SpainNEO-TOMIZOL 5 mg COMPRIMIDOSFerrer Internacional S.A.
- GermanyCarbimazol 1 A Pharma1 A Pharma Gmbh
Authorised across Europe · EMA
The same active substance is authorised in 11 EEA countries. Names it is sold under:
- Cyprus · Carbimazole Remedica
- Germany · Carbimazol 1 A Pharma, Carbimazol Aristo
- Denmark · Neo-Mercazole
- Spain · Neo-Tomizol
- Finland · Tyrazol
- France · Neo-Mercazole
- United Kingdom (Northern Ireland) · Carbimazole, Carbimazole Activase Pharmaceuticals
- Greece · Thyrostat
- Malta · Carbimazole Remedica, Carbimazole Renata Pharmaceuticals (Ireland)
- Norway · Neo-Mercazole
- Portugal · Carbimazole Renata, Carbimazole Renata 20 Mg Comprimidos
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9a038fd9-e7f4-4ed1-8677-8490edb0cd1e GET /v1/drugs/9a038fd9-e7f4-4ed1-8677-8490edb0cd1e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tablet",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"H03BB01"
],
"strength": null,
"pa_number": "PA22865/006/001",
"substances": [
"Carbimazole"
],
"legal_basis": "Generic application (Article 10(1) of Directive No 2001/83/EC)",
"market_info": "Marketed",
"authorised_at": "18/11/2022",
"dispensing_status": "Product subject to prescription which may be renewed (B)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about carbimazole.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.